Id: acc2563
Group: 2sens
Protein: PKM2
Gene Symbol: PKM
Protein Id: P14618
Protein Name: KPYM_HUMAN
PTM: glycosylation
Site: Arg399
Site Sequence: YHLQLFEELRRLAPITSDPTE
Disease Category: Cancer
Disease: Cancer
Disease Subtype:
Disease Cellline:
Disease Info:
Drug: MG
Drug Info: Atogepant (Qulipta) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults.
Effect: inhibit
Effect Info: "Glycosylation of PKM2 protein and others inhibit GAPDH in tumor cells, without clearly stating the activity."
Note:
Score: 5.0
Pubmed(PMID): 26911935
Sentence Index:
Sentence:

Sequence & Structure:

MSKPHSEAGTAFIQTQQLHAAMADTFLEHMCRLDIDSPPITARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQKGADFLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYHLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPVP

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - D Psoriasis Acetylation 32679047
K 433 D Hepatocellular carcinoma Acetylation 34016961
Y 105 P Lung adenocarcinoma Phosphorylation 36428781
Y 105 P Pancreatic cancer Phosphorylation 36244646
S 37 P Glioblastoma Phosphorylation 27485204
S 37 P Breast cancer Phosphorylation 34966685
S 100 U Triple-negative breast cancer Phosphorylation 34244606
S 37 U Triple-negative breast cancer Phosphorylation 34185676
S 37 U Non-small cell lung cancer Phosphorylation 35790734
S 37 U Colorectal cancer Phosphorylation 35973989
S 222 U Glioblastoma Phosphorylation 35048565
- - U Diffuse large B-cell lymphoma Phosphorylation 34168996
Y 105 U Head and neck squamous cell carcinoma Phosphorylation 35054968
- - U Ovarian cancer Ubiquitination 34382324
Y 105 U Cervical cancer Phosphorylation 33800513
- - U Gastric cancer Ubiquitination 37624791
- - U Hepatocellular carcinoma Ubiquitination 37594129
Y 105 U Prostate cancer Phosphorylation 36400183
Y 105 U Breast cancer Phosphorylation 29440169
- - U Liver fibrosis Phosphorylation 35140065
T 45 U Lung cancer Phosphorylation 36198360
T 45 U Cancer Phosphorylation 36417819
T 328 U Glioblastoma multiforme Phosphorylation 30297868
S 37 U Lymphangiomyomatosis Phosphorylation 32078667
S 37 U Glioblastoma multiforme Phosphorylation 23178880
K 433 U Breast cancer Acetylation 24120661
K 305 U Prostate cancer Acetylation 21700219
K 433 U Leukemia Acetylation 29641204
K 433 U Hepatocellular carcinoma Acetylation 34016961 26787900
K 305 U Breast cancer Acetylation 27197174
K 62 U Hepatocellular carcinoma Acetylation 33279948

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: